RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial.

Fatma Doener,Henoch S Hong,Ingo Meyer, Keyvan Tadjalli-Mehr,Angelika Daehling,Regina Heidenreich,Sven D Koch,Mariola Fotin-Mleczek,Ulrike Gnad-Vogt

Vaccine（2019）

引用 41|浏览22

暂无评分

摘要

Doses of 25 and 50 µg CV8102 appeared safe and with an acceptable reactogenicity profile while significantly enhancing the immunogenicity of fractional doses of rabies vaccine. EudraCT No. 2013-004514-18.

查看译文

关键词

Adjuvant,RNA,Rabies,Prophylactic vaccines,Safety,Immunostimulatory

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要